Bevacizumab in ophthalmology: the controversy moves forward.
Gillies
Mark C
MC
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000818:Animals; D000869:Anterior Eye Segment / Q000098:blood supply; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003315:Cornea / Q000098:blood supply; D003362:Cost-Benefit Analysis; D005123:Eye / Q000098:blood supply*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009885:Ophthalmology / Q000379:methods*; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab